Effect of chondroitin sulfate on turpentine-induced down-regulation of CYP1A2 and CYP3A6

• Published in: Carbohydrate research 2012-07, Vol.355, p.63-68
• Main Authors: Iovu, Mirela-Onita, Héroux, Lucie, Vergés, Josep, Montell, Eulália, Paiement, Jacques, du Souich, Patrick
• Format: Article
• Language: English
• Subjects: Animals; Aryl Hydrocarbon Hydroxylases - biosynthesis; Aryl Hydrocarbon Hydroxylases - genetics; Aryl Hydrocarbon Hydroxylases - metabolism; Chondroitin sulfate; Chondroitin Sulfates - chemistry; Chondroitin Sulfates - pharmacology; CYP1A2; CYP3A6; cytochrome P-450; Cytochrome P-450 CYP1A2 - biosynthesis; Cytochrome P-450 CYP1A2 - genetics; Cytochrome P-450 CYP1A2 - metabolism; Cytochrome P450; Down-Regulation - drug effects; Enzyme Inhibitors - chemistry; Enzyme Inhibitors - pharmacology; hepatocytes; Inflammation; Inflammation - chemically induced; Inflammation - drug therapy; Male; messenger RNA; NF-κB; nitric oxide; protein synthesis; Rabbits; RNA, Messenger - genetics; RNA, Messenger - metabolism; Structure-Activity Relationship; transcription factor NF-kappa B; Turpentine - pharmacology
• ISSN: 0008-6215; 1873-426X
• DOI: 10.1016/j.carres.2012.04.015

[Display omitted] ► CS is an anti-inflammatory drug used for long-term treatment of patients with OA. ► Inflammatory reactions down-regulated many isoforms of the cytochrome P450. ► CS does not modulate baseline cytochrome P450. ► CS does not prevent pre-transcriptional cytochrome P450 down-regulation. ► CS impedes CYP3A4 post-transcriptional down-regulation. This study aimed to assess whether chronic administration of chondroitin sulfate (CS) affects baseline expression of cytochrome P450 isoforms and impedes the decrease in expression and activity of CYP1A2 and CYP3A6 in rabbits with a turpentine-induced inflammatory reaction (TIIR). Seven groups of 5 rabbits, 3 control groups and 4 receiving 20mg/kg/day of CS for 20 and 30days, were used. The rabbits of 1 control group and 2 groups receiving CS had a TIIR; finally, the rabbits of one of the control groups remained in the animal facilities for 30days to assess the effect of time and environment on cytochrome P450. In control rabbits, intake of CS for 20 and 30days did not affect CYP3A6, CYP1A2 and NADPH cytochrome P450 reductase (CPR) mRNA, protein expression and activity. Compared with control rabbits, the TIIR not only reduced mRNA, protein expression and activity of CYP3A6 and CYP1A2 but also that of CPR. In rabbits with TIIR, CS prevented the decrease of CYP3A6 expression but not the reduction in activity. CS did not impede TIIR-induced down-regulation of CYP1A2. Hepatic NO concentrations and NF-κB nuclear translocation were increased by the TIIR, effect reversed by CS. In vitro, in hepatocytes, CS did not alter the expression and activity of CYP3A6, CYP1A2, and CPR. In conclusion, oral CS elicits a systemic effect but does not affect CYP1A2, CYP3A6, and CPR in control rabbits, although in rabbits with TIIR, CS prevents CYP3A6 protein down-regulation but not that of CYP1A2.